Skip to main
OTLK
OTLK logo

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc is positioned favorably in the biopharmaceutical sector with the successful marketing authorization of ONS-5010/LYTENAVA for treating wet age-related macular degeneration in the European Union and United Kingdom. The company's promise is further amplified by its comprehensive product pipeline, which includes eight NORSES addressing unmet patient needs and serving as a potential first line therapy for ophthalmic anti-VEGF treatments. Overall, the positive outlook is supported by the clinical advancements in ONS-5010 and the potential to meet significant demands in the ophthalmic market.

Bears say

Outlook Therapeutics Inc faces a challenging environment due to its reliance on ONS-5010 as the sole active development program, raising concerns about the company's financial stability and potential need for additional financing to reach profitability. The negative outlook is further compounded by the uncertainty surrounding the success of ongoing clinical trials, particularly after missing the primary endpoint of the NORSE 8 study at 8 weeks, which raises questions about the effectiveness and regulatory approval of ONS-5010. Additionally, the competitive landscape may pose significant risks, as novel drugs and biosimilars could undermine ONS-5010's market position if approved.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.